

Date: Tuesday, 24th August 2021 Our Ref: MB/SS FOI 4861

> Sid Watkins Building Lower Lane Fazakerley Liverpool L9 7BB Tel: 01515253611 Fax: 01515295500 Direct Line: 01515563038

# **Re: Freedom of Information Request FOI 4861**

We are writing in response to your request submitted under the Freedom of Information Act, received in this office on 19th August 2021.

Your request was as follows:

Q1. How many patients has your trust treated (for any disease) in the last 6 months with the following treatments:

- Doptelet (avatrombopag)
- Jakavi (ruxolitinib)
- Nplate (romiplostim)
- Revolade (eltrombopag)
- Tavlesse (fostamatinib)
- Hydroxycarbamide

hydroxycarbamide - 2 patients other drugs - none

Q2. In the last 6 months, how many patients has your trust treated for:

- Immune thrombocytopenia (ICD10 code D69.3)
- Myelofibrosis (ICD10 code D47.4)
- Myelofibrosis (ICD10 code D47.4) patients over the age 65

The Walton Centre NHS Foundation Trust is a Specialist Neuroscience Tertiary Care Centre; we would not receive referrals to treat patients for the condition you have mentioned above, therefore we cannot provide this information.

Q3. Of the patients treated for immune thrombocytopenia (ICD10 code D69.3) in the last 6 months, how many were treated with:







Mycophenolate mofetil

- Rituximab
- Surgery (splenectomy)

I can confirm in accordance with Section 1 of the Freedom of Information Act 2000 (FOIA) that we do not hold the information you have requested as pharmacy only holds information on medication issued and does not hold information about the indication, therefore we cannot provide this information.

Under the FOIA, we are not required to create this information in order to answer your request. I should explain that the FOIA is to do with transparency of information held by public authorities. It gives an individual the right to access recorded information held by public authorities. The FOIA does not require public authorities to generate information, or to answer questions, provide explanations or give opinions, unless this is recorded information that they already hold.

Q4. How many myelofibrosis (ICD10 code D47.4) patients has your trust diagnosed in the past 3 years?

• Of the myelofibrosis patients diagnosed in the last 3 years, how many were treated in the past 6 months with Hydroxycarbamide?

• Of the myelofibrosis patients diagnosed in the last 3 years, how many have received no active treatment in the past 6 months?

### As question 2.

Q5. Does you trust participate in any ongoing clinical trials for immune thrombocytopenia (ITP)? If so, can you please provide the name of each trial along with the number of patients taking part?

### N/A - As question 2.

Q6. Does you trust participate in any ongoing clinical trials for myelofibrosis? If so, can you please provide the name of each trial along with the number of patients taking part?

N/A - As question 2.

Please see our response above in blue.

### **Re-Use of Public Sector Information**

All information supplied by the Trust in answering a request for information (RFI) under the Freedom of Information Act 2000 will be subject to the terms of the Re-use of Public Sector Information Regulations 2005, Statutory Instrument 2005 No. 1515 which came into effect on 1st July 2005.

Under the terms of the Regulations, the Trust will licence the re-use of any or all information supplied if being used in a form and for the purpose other than which it was originally supplied. This license for re-use will be in line with the requirements of the Regulations and the licensing terms and fees as laid down by the Office of Public Sector Information (OPSI). Most licenses will be free; however the Trust reserves the right, in certain circumstances, to charge a fee for the re-use of some information which it deems to be of commercial value.







Excellence in Neuroscience



Further information can be found at www.opsi.gov.uk where a sample license terms and fees can be found with guidance on copyright and publishing notes and a Guide to Best Practice and regulated advice and case studies, at www.opsi.gov.uk/advice/psi-regulations/index.htm

If you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to the Freedom of Information Office at the address above.

# Please remember to quote the reference number, FOI 4861 in any future communications.

If you are not content with the outcome of the internal review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioners Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF.

Yours sincerely *Mike Burns* **Mr. Mike Burns, Executive Lead for Freedom of Information** 



